Refine
Year of publication
Document Type
- Preprint (633)
- Article (370)
- Contribution to a Periodical (3)
- Working Paper (2)
Has Fulltext
- yes (1008)
Is part of the Bibliography
- no (1008)
Keywords
- Heavy Ion Experiments (19)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- Heavy-ion collision (6)
- Collective Flow (4)
- Jets (4)
- LHC (4)
- Quark-Gluon Plasma (4)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- ALICE experiment (2)
- COVID-19 (2)
- Charm physics (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Germany (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- QCD (2)
- acute myeloid leukemia (2)
- childhood acute myeloid leukemia (2)
- relapse (2)
- salvage therapy (2)
- 3years (1)
- 900 GeV (1)
- ALICE (1)
- ALICE detector (1)
- ALK-rearranged NSCLC (1)
- Active middle ear implants (1)
- Acute kidney injury (1)
- Alcorrín (1)
- Animal model (1)
- Anti-nuclei (1)
- Auditory system (1)
- Autologous stem cell transplantation (1)
- Beauty production (1)
- Bike-Sharing (1)
- Bipolar disorder (1)
- Blood loss (1)
- Bone conduction devices (1)
- Bone tumor (1)
- Boosted Jets (1)
- Bronce Final (1)
- CTLA-4 (1)
- CVD biomarker (1)
- Car-Sharing (1)
- Centrality Class (1)
- Centrality Selection (1)
- Cleanliness level (1)
- Collective Flow, (1)
- Colloids (1)
- Colon capsule endoscopy (1)
- Complementation rate (1)
- Congenital ocular motor apraxia (1)
- Consensus statement (1)
- Couch tracking (1)
- DME (1)
- DNA methylation (1)
- Deutschland (1)
- Diagnostic markers (1)
- EBV (1)
- Early Iron Age (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Elektromobilität (1)
- Elliptic flow (1)
- Endocrine cancer (1)
- Estrecho de Gibraltar (1)
- Extended donor criteria (1)
- Fibre/foam sandwich radiator (1)
- Flottenkonzepte (1)
- Forschung (1)
- Fortifica (1)
- General relativity (1)
- General relativity equations & solutions (1)
- Gimbaled tracking (1)
- Graft function (1)
- Graft survival (1)
- HES (1)
- HNO (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hard Scattering (1)
- Health policy (1)
- Heavy Ion Experiment (1)
- Heavy Quark Production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- High-dose chemotherapy (1)
- Hydroxyethyl starch (1)
- ILUVIEN (1)
- IgG4-related disease (1)
- Incomplete colonoscopy (1)
- Indeterminate biliary stricture (1)
- Indigenous Peoples (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Jet Physics (1)
- Jet Substructure (1)
- Joubert syndrome (1)
- Krebsforschung (1)
- LTER (1)
- Ladeinfrastruktur (1)
- Late Bronze Age (1)
- Lehre (1)
- Lenalidomide (1)
- Lepton-Nucleon Scattering (experiments) (1)
- Liver transplantation (1)
- Long‐term ecosystem research (1)
- Low volume prep (1)
- MLC tracking (1)
- Marginal grafts (1)
- Minimum Bias (1)
- Mixed hearing loss (1)
- Mobil-Stationen (1)
- Molar tooth sign (1)
- Monte Carlo (1)
- Moviprep (1)
- Multi-Parton Interactions (1)
- Multi-stakeholder approach (1)
- Multi-wire proportional drift chamber (1)
- Multiple myeloma (1)
- Neural network (1)
- Neuroendocrine cancer (1)
- Next-generation sequencing (1)
- Nucleosynthesis in explosive environments (1)
- ORL (1)
- Organ motion (1)
- Organ rinse (1)
- Organ shortage (1)
- Otorhinolaryngology (1)
- PCR (1)
- PD-1 (1)
- PYTHIA (1)
- Particle and Resonance Production (1)
- Pedelecs (1)
- Phoenician Writing (1)
- Phoenicians (1)
- Phospho-soda (1)
- PillCamColon2 (1)
- Polyps (1)
- Primera Edad del Hierro (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Quark Deconfinement (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quarkonium (1)
- Rabbit (1)
- Radiofrequency ablation (1)
- Rapidity Range (1)
- Rehabilitation (1)
- Relapse (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Research (1)
- Research infrastructure (1)
- Residency (1)
- Resolution Parameter (1)
- Retro-IDEAL (1)
- Robotic tracking (1)
- SARS-CoV-2 (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- Second-line treatment (1)
- Single electrons (1)
- Site networks (1)
- Specialist training (1)
- Steroid (1)
- Strait of Gibraltar (1)
- Surgery (1)
- Systematic Uncertainty (1)
- TP53 mutation status (1)
- TR (1)
- Tacrolimus (1)
- Teaching (1)
- Technical data (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transient & explosive astronomical phenomena (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trauma (1)
- Trigger (1)
- Tumor therapy (1)
- Umweltbilanz (1)
- University hospitals (1)
- Universitätskliniken (1)
- VX-2 (1)
- Vector Boson Production (1)
- Volume therapy (1)
- Weiterbildung (1)
- Xenon-based gas mixture (1)
- adolescents’ health (1)
- advanced melanoma (1)
- allocation (1)
- bile duct stenosis (1)
- biliary stricture (1)
- biofilm (1)
- child (1)
- cholangiocarcinoma (1)
- complete response (1)
- dE/dx (1)
- dental implant (1)
- discontinuation (1)
- disease progression (1)
- ectosomes (1)
- electrolytic cleaning (1)
- endoscopic retrograde cholangiopancreatography (1)
- endoscopy (1)
- eosinophilic cholangitis (1)
- escritura fenicia (1)
- exosomes (1)
- extracellular vesicles (1)
- fenicios (1)
- fortificación, (1)
- fourth (1)
- graft (1)
- guidelines (1)
- heavy ion experiments (1)
- immune checkpoint blockade (1)
- immunohistochemistry (1)
- indígenas (1)
- infection (1)
- kidney (1)
- kidney transplantation (1)
- liver metastasis (1)
- liver transplantation (1)
- loss (1)
- microdosing (1)
- microparticles (1)
- microsatellite instability (1)
- microvesicles (1)
- minimal information requirements (1)
- multidrug resistance (1)
- multisite cooperation (1)
- neutralizing antibodies (1)
- nocardia (1)
- nocardiosis (1)
- paediatric nephrology (1)
- pediatric (1)
- pediatric patients (1)
- periimplantitis (1)
- perio-prosthetic joint infection (1)
- personalized oncology (1)
- pp collisions (1)
- primary sclerosing cholangitis (1)
- pulmonary nocardiosis (1)
- quark gluon plasma (1)
- re-transplantation (1)
- recurrent cholangitis (1)
- repeated (1)
- reproducibility (1)
- research consortium (1)
- rigor (1)
- risk factor progression (1)
- risk factors (1)
- second-line immunotherapy (1)
- sequential ALK-inhibitor therapy (1)
- short-course antibiotic therapy (1)
- spike protein (1)
- standardization (1)
- survival (1)
- targeted therapy (1)
- third (1)
- transfer (1)
- transition (1)
- translational cancer research (1)
- treatment resistance (1)
- uveal melanoma (1)
- variants of concern (1)
Institute
- Physik (957)
- Frankfurt Institute for Advanced Studies (FIAS) (886)
- Informatik (855)
- Medizin (36)
- Informatik und Mathematik (3)
- Präsidium (3)
- Geographie (2)
- Geowissenschaften (2)
- Hochschulrechenzentrum (2)
- Biowissenschaften (1)
Background: We analyzed whether co-occurring mutations influence the outcome of systemic therapy in ALK-rearranged non-small-cell lung cancer (NSCLC).
Patients and methods: ALK-rearranged stage IIIB/IV NSCLC patients were analyzed with next-generation sequencing and fluorescence in situ hybridization analyses on a centralized diagnostic platform. Median progression-free survival (PFS) and overall survival (OS) were determined in the total cohort and in treatment-related sub-cohorts. Cox regression analyses were carried out to exclude confounders.
Results: Among 216 patients with ALK-rearranged NSCLC, the frequency of pathogenic TP53 mutations was 23.8%, while other co-occurring mutations were rare events. In ALK/TP53 co-mutated patients, median PFS and OS were significantly lower compared with TP53 wildtype patients [PFS 3.9 months (95% CI: 2.4–5.6) versus 10.3 months (95% CI: 8.6–12.0), P < 0.001; OS 15.0 months (95% CI: 5.0–24.9) versus 50.0 months (95% CI: 22.9–77.1), P = 0.002]. This difference was confirmed in all treatment-related subgroups including chemotherapy only [PFS first-line chemotherapy 2.6 months (95% CI: 1.3–4.1) versus 6.2 months (95% CI: 1.8–10.5), P = 0.021; OS 2.0 months (95% CI: 0.0–4.6) versus 9.0 months (95% CI: 6.1–11.9), P = 0.035], crizotinib plus chemotherapy [PFS crizotinib 5.0 months (95% CI: 2.9–7.2) versus 14.0 months (95% CI: 8.0–20.1), P < 0.001; OS 17.0 months (95% CI: 6.7–27.3) versus not reached, P = 0.049] and crizotinib followed by next-generation ALK-inhibitor [PFS next-generation inhibitor 5.4 months (95% CI: 0.1–10.7) versus 9.9 months (95% CI: 6.4–13.5), P = 0.039; OS 7.0 months versus 50.0 months (95% CI: not reached), P = 0.001).
Conclusions: In ALK-rearranged NSCLC co-occurring TP53 mutations predict an unfavorable outcome of systemic therapy. Our observations encourage future research to understand the underlying molecular mechanisms and to improve treatment outcome of the ALK/TP53 co-mutated subgroup.
Exported proteases of Helicobacter pylori (H. pylori) are potentially involved in pathogen-associated disorders leading to gastric inflammation and neoplasia. By comprehensive sequence screening of the H. pylori proteome for predicted secreted proteases, we retrieved several candidate genes. We detected caseinolytic activities of several such proteases, which are released independently from the H. pylori type IV secretion system encoded by the cag pathogenicity island (cagPAI). Among these, we found the predicted serine protease HtrA (Hp1019), which was previously identified in the bacterial secretome of H. pylori. Importantly, we further found that the H. pylori genes hp1018 and hp1019 represent a single gene likely coding for an exported protein. Here, we directly verified proteolytic activity of HtrA in vitro and identified the HtrA protease in zymograms by mass spectrometry. Overexpressed and purified HtrA exhibited pronounced proteolytic activity, which is inactivated after mutation of Ser205 to alanine in the predicted active center of HtrA. These data demonstrate that H. pylori secretes HtrA as an active protease, which might represent a novel candidate target for therapeutic intervention strategies.
Dieser Bericht stellt die wesentlichen Ergebnisse der sozialwissenschaftlichen und ökologischen Begleitforschung in der Modellregion Elektromobilität Rhein-Main (SÖB) dar. Dabei wird zunächst das Projektumfeld vorgestellt, indem auf die Rahmenbedingungen des Förderprogramms sowie weitere Programme und Projekte im Bereich Elektromobilität eingegangen wird. Im zweiten Kapitel wird das Projektkonsortium und dessen Einbettung in die Modellregion Rhein-Main erläutert, sowie die Verknüpfung mit der überregionalen Begleitforschung der Nationalen Organisation Wasser- und Brennstoffzellentechnologie (NOW). Im Kapitel 3 wird das Forschungsdesign der SÖB skizziert. Dazu werden einige Erkenntnisse aus der ersten Förderperiode beleuchtet, die für die Forschungsziele der aktuellen Förderperiode ausschlaggebend waren. Des Weiteren erfolgt eine Ausführung der methodischen Vorgehensweisen der Projektpartner. Das darauf folgende Kapitel 4 stellt die wesentlichen Ergebnisse des Projekts dar. Dabei wurde bewusst versucht, die verschie¬denen Erkenntnisse der einzelnen Partner thematisch miteinander zu verknüpfen. Aus den Ergeb¬nissen wurden Handlungsempfehlungen für verschiedene Bereiche und Akteure generiert, die in Kapitel 5 einfließen. Abschließend rundet ein Fazit mit zusammenfassenden Erkenntnissen den Bericht ab.
TRIANNI mice carry an entire set of human immunoglobulin V region gene segments and are a powerful tool to rapidly isolate human monoclonal antibodies. After immunizing these mice with DNA encoding the spike protein of SARS-CoV-2 and boosting with spike protein, we identified 29 hybridoma antibodies that reacted with the SARS-CoV-2 spike protein. Nine antibodies neutralize SARS-CoV-2 infection at IC50 values in the subnanomolar range. ELISA-binding studies and DNA sequence analyses revealed one cluster of three clonally related neutralizing antibodies that target the receptor-binding domain and compete with the cellular receptor hACE2. A second cluster of six clonally related neutralizing antibodies bind to the N-terminal domain of the spike protein without competing with the binding of hACE2 or cluster 1 antibodies. SARS-CoV-2 mutants selected for resistance to an antibody from one cluster are still neutralized by an antibody from the other cluster. Antibodies from both clusters markedly reduced viral spread in mice transgenic for human ACE2 and protected the animals from SARS-CoV-2-induced weight loss. The two clusters of potent noncompeting SARS-CoV-2 neutralizing antibodies provide potential candidates for therapy and prophylaxis of COVID-19. The study further supports transgenic animals with a human immunoglobulin gene repertoire as a powerful platform in pandemic preparedness initiatives.
Aim: To evaluate the ability of PillCamColon2 to visualize colonic segments missed by incomplete optical colonoscopy (OC) and to assess the diagnostic yield.
Methods: This prospective multicentre study included 81 patients from nine centres who underwent second-generation colon capsule endoscopy (CCE) following incomplete OC performed by an experienced gastroenterologist (> 1000 colonoscopies). Patients with stenosis were excluded. According to patient preferences, CCE was performed the following day (protocol A) after staying on clear liquids and 0.75 L Moviprep in the morning or within 30 d after new split-dose Moviprep (protocol B). Boosts consisted of 0.75 L and 0.25 L Moviprep, and phospho-soda was given as a rescue if the capsule was not excreted after seven hours.
Results: Seventy-four patients were analysed (51% of them in group A; 49% in group B). Bowel cleansing was adequate in 67% of cases, and CCE could visualize colonic segments missed by incomplete colonoscopy in 90% of patients under protocol A and 97% of patients under protocol B (P = 0.35, n.s.). Significant polyps including adenocarcinoma were detected in 24% of cases. Detection rates for all polyps and significant polyps per patient were similar in both protocols. Polyps were found predominantly in the right colon (86%) in segments that were not reached by OC. Extracolonic findings - such as reflux esophagitis, suspected Barrett esophagus, upper GI-bleeding, gastric polyps, gastric erosions and angiectasia - were detected in eight patients. PillCamColon2 capsule was retained in the ileum of one patient (1.4%) without symptoms and removed during an uneventful resection for unknown Crohn’s disease that was diagnosed as the cause of anemia, which was the indication for colonoscopy. CCE was well tolerated. One patient suffered from self-limiting vomiting after consuming the phospho-soda.
Conclusion: Second-generation CCE using a low-volume preparation is useful after incomplete OC, and it allows for the detection of additional relevant findings, but cleansing efficiency could be improved.
Purpose: A study of real-time adaptive radiotherapy systems was performed to test the hypothesis that, across delivery systems and institutions, the dosimetric accuracy is improved with adaptive treatments over non-adaptive radiotherapy in the presence of patient-measured tumor motion.
Methods and materials: Ten institutions with robotic(2), gimbaled(2), MLC(4) or couch tracking(2) used common materials including CT and structure sets, motion traces and planning protocols to create a lung and a prostate plan. For each motion trace, the plan was delivered twice to a moving dosimeter; with and without real-time adaptation. Each measurement was compared to a static measurement and the percentage of failed points for γ-tests recorded.
Results: For all lung traces all measurement sets show improved dose accuracy with a mean 2%/2 mm γ-fail rate of 1.6% with adaptation and 15.2% without adaptation (p < 0.001). For all prostate the mean 2%/2 mm γ-fail rate was 1.4% with adaptation and 17.3% without adaptation (p < 0.001). The difference between the four systems was small with an average 2%/2 mm γ-fail rate of <3% for all systems with adaptation for lung and prostate.
Conclusions: The investigated systems all accounted for realistic tumor motion accurately and performed to a similar high standard, with real-time adaptation significantly outperforming non-adaptive delivery methods.
Aims: Averaged measurements, but not the progression based on multiple assessments of carotid intima-media thickness, (cIMT) are predictive of cardiovascular disease (CVD) events in individuals. Whether this is true for conventional risk factors is unclear.
Methods and results: An individual participant meta-analysis was used to associate the annualised progression of systolic blood pressure, total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with future cardiovascular disease risk in 13 prospective cohort studies of the PROG-IMT collaboration (n = 34,072). Follow-up data included information on a combined cardiovascular disease endpoint of myocardial infarction, stroke, or vascular death. In secondary analyses, annualised progression was replaced with average. Log hazard ratios per standard deviation difference were pooled across studies by a random effects meta-analysis. In primary analysis, the annualised progression of total cholesterol was marginally related to a higher cardiovascular disease risk (hazard ratio (HR) 1.04, 95% confidence interval (CI) 1.00 to 1.07). The annualised progression of systolic blood pressure, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol was not associated with future cardiovascular disease risk. In secondary analysis, average systolic blood pressure (HR 1.20 95% CI 1.11 to 1.29) and low-density lipoprotein cholesterol (HR 1.09, 95% CI 1.02 to 1.16) were related to a greater, while high-density lipoprotein cholesterol (HR 0.92, 95% CI 0.88 to 0.97) was related to a lower risk of future cardiovascular disease events.
Conclusion: Averaged measurements of systolic blood pressure, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol displayed significant linear relationships with the risk of future cardiovascular disease events. However, there was no clear association between the annualised progression of these conventional risk factors in individuals with the risk of future clinical endpoints.
When binary systems of neutron stars merge, a very small fraction of their rest mass is ejected, either dynamically or secularly. This material is neutron-rich and its nucleosynthesis provides the astrophysical site for the production of heavy elements in the Universe, together with a kilonova signal confirming neutron-star mergers as the origin of short gamma-ray bursts. We perform full general-relativistic simulations of binary neutron-star mergers employing three different nuclear-physics equations of state (EOSs), considering both equal- and unequal-mass configurations, and adopting a leakage scheme to account for neutrino radiative losses. Using a combination of techniques, we carry out an extensive and systematic study of the hydrodynamical, thermodynamical, and geometrical properties of the matter ejected dynamically, employing the WinNet nuclear-reaction network to recover the relative abundances of heavy elements produced by each configurations. Among the results obtained, three are particularly important. First, we find that, within the sample considered here, both the properties of the dynamical ejecta and the nucleosynthesis yields are robust against variations of the EOS and masses. Second, using a conservative but robust criterion for unbound matter, we find that the amount of ejected mass is ≲10−3 M⊙, hence at least one order of magnitude smaller than what normally assumed in modelling kilonova signals. Finally, using a simplified and gray-opacity model we assess the observability of the infrared kilonova emission finding, that for all binaries the luminosity peaks around ∼1=2 day in the H-band, reaching a maximum magnitude of −13, and decreasing rapidly after one day.
Background: Radiofrequency ablation is a minimal invasive therapy in the treatment of bone metastases. In this study we present a new ablation system enabling an ablation in multiple directions and with an adaptable size and shape.
Material and methods: VX-2 tumor was used for the induction of experimental bone metastases in the femur of six New Zealand white rabbits. X-ray imaging as well as CT and MRI scans before and after treatment was carried out. After detecting bone tumor, radiofrequency ablation was performed. The ablation instrument contained a 10 g bipolar, articulated extendable electrode and a proprietary generator with an impedance controlled algorithm. All bones and the soft tissue were examined histologically.
Results: All animals developed local bone tumor. Mean duration until first osteolytic lesions on CT-scans was 48±14 days. The mean lesion area was 26 mm(2). No systemic tumor spread was seen. 6 radiofrequency procedures were carried out with a mean application time of 6 min±2:30 and an average temperature in the region of effect of 55 °C±4. MRI imaging demonstrated an ablation zone of 23±6 mm around the electrode. Histopathology showed an extensive heat necrosis with no remaining tumor cells in the ablation area.
Conclusion: Radiofrequency ablation is a quickly developing treatment option on the field of minimal invasive bone tumor therapy. The electrode enables an ablation adapted to size and shape of the metastases. Further clinical studies are necessary to test and enhance this radiofrequency system.
Objectives: Stenosis of the biliary anastomosis predisposes liver graft recipients to bacterial cholangitis. Antibiotic therapy (AT) is performed according to individual clinical judgment, but duration of AT remains unclear.
Methods: All liver graft recipients with acute cholangitis according to the Tokyo criteria grade 1 and 2 after endoscopic retrograde cholangiography (ERC) were included. Outcome of patients treated with short AT (<7 days) was compared to long AT (>6 days). Recurrent cholangitis (RC) within 28 days was the primary end point.
Results: In total, 30 patients were included with a median of 313 (range 34–9849) days after liver transplantation until first proven cholangitis. Among 62 cases in total, 51/62 (82%) were graded as Tokyo-1 and 11/62 (18%) as Tokyo-2. Overall median duration of AT was 6 days (1–14) with 36 cases (58%) receiving short AT and 26 (42%) receiving long AT. RC was observed in 10 (16%) cases, without significant difference in occurrence of RC in short versus long AT cases. CRP and bilirubin were significantly higher in patients with long AT, while low serum albumin and low platelets were associated with risk of RC.
Conclusion: A shorter antibiotic course than 7 days shows good results in selected, ERC-treated patients for post-transplantation biliary strictures.